Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers
Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly de...
Gespeichert in:
Veröffentlicht in: | Journal of medical virology 2021-03, Vol.93 (3), p.1766-1769 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1769 |
---|---|
container_issue | 3 |
container_start_page | 1766 |
container_title | Journal of medical virology |
container_volume | 93 |
creator | Capetti, Amedeo F. Borgonovo, Fabio Morena, Valentina Lupo, Angelica Cossu, Maria Vittoria Passerini, Matteo Dedivitiis, Gianfranco Rizzardini, Giuliano |
description | Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15–20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS‐CoV‐2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared “cured” (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects. |
doi_str_mv | 10.1002/jmv.26485 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7891345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2481910066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5095-433cc6eda294b64b4c543c34fedf2ed47fccdd6538fce1a525b007bfec8af1973</originalsourceid><addsrcrecordid>eNp1kctKAzEYhYMotl4WvoAMuHIxmmSSzMxGkOIVRbDabcjk0klpJzWZqt35CD6jT2JqtejCTf7A-f6TQw4AewgeIQjx8WjyfIQZKega6CJYsrSEOVoHXYgISxlDtAO2QhhBCIsS403QyXBRoKh2gerXzrcfb--t9pPENrWtbGtdkziT9E_v-1HpuUE8cVLNk3quvBvqJplq716t0nFjcQ82tLppk0YEN62FnzdDLcaJFN7bqO6ADSPGQe9-z23weH720LtMb-4urnqnN6mksKQpyTIpmVYCl6RipCKSkkxmxGhlsFYkN1IqxWhWGKmRoJhWEOaV0bIQBpV5tg1Olr7TWTXRSsZIXoz51NtJzMSdsPyv0tiaD90zz4sSZYRGg4NvA--eZjq0fORmvomZOSYFKuNvMxapwyUlvQvBa7N6AUG-KITHQvhXIZHd_x1pRf40EIHjJfBix3r-vxO_vh0sLT8B3mGbHQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2481910066</pqid></control><display><type>article</type><title>Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Capetti, Amedeo F. ; Borgonovo, Fabio ; Morena, Valentina ; Lupo, Angelica ; Cossu, Maria Vittoria ; Passerini, Matteo ; Dedivitiis, Gianfranco ; Rizzardini, Giuliano</creator><creatorcontrib>Capetti, Amedeo F. ; Borgonovo, Fabio ; Morena, Valentina ; Lupo, Angelica ; Cossu, Maria Vittoria ; Passerini, Matteo ; Dedivitiis, Gianfranco ; Rizzardini, Giuliano</creatorcontrib><description>Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15–20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS‐CoV‐2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared “cured” (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.26485</identifier><identifier>PMID: 32881014</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Burning ; Carrier State - drug therapy ; Carrier State - virology ; Chemical agents ; Coronaviridae ; Coronaviruses ; COVID-19 ; COVID-19 - drug therapy ; Female ; Humans ; Hydrogen peroxide ; Hydrogen Peroxide - therapeutic use ; Male ; Middle Aged ; Mucosa ; nasopharingeal ; Nasopharynx - virology ; Oxidants - therapeutic use ; persistent ; Physicians ; Respiratory diseases ; SARS-CoV-2 - drug effects ; SARS-CoV-2 - isolation & purification ; SARS‐CoV‐2 ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Short Communication ; Short Communications ; Side effects ; swab ; Treatment Outcome ; Viral diseases ; Virology ; Virus Shedding - drug effects ; Viruses</subject><ispartof>Journal of medical virology, 2021-03, Vol.93 (3), p.1766-1769</ispartof><rights>2020 The Authors. published by Wiley Periodicals LLC</rights><rights>2020 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5095-433cc6eda294b64b4c543c34fedf2ed47fccdd6538fce1a525b007bfec8af1973</citedby><cites>FETCH-LOGICAL-c5095-433cc6eda294b64b4c543c34fedf2ed47fccdd6538fce1a525b007bfec8af1973</cites><orcidid>0000-0003-4633-1035</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjmv.26485$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjmv.26485$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32881014$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Capetti, Amedeo F.</creatorcontrib><creatorcontrib>Borgonovo, Fabio</creatorcontrib><creatorcontrib>Morena, Valentina</creatorcontrib><creatorcontrib>Lupo, Angelica</creatorcontrib><creatorcontrib>Cossu, Maria Vittoria</creatorcontrib><creatorcontrib>Passerini, Matteo</creatorcontrib><creatorcontrib>Dedivitiis, Gianfranco</creatorcontrib><creatorcontrib>Rizzardini, Giuliano</creatorcontrib><title>Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15–20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS‐CoV‐2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared “cured” (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects.</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Burning</subject><subject>Carrier State - drug therapy</subject><subject>Carrier State - virology</subject><subject>Chemical agents</subject><subject>Coronaviridae</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrogen peroxide</subject><subject>Hydrogen Peroxide - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mucosa</subject><subject>nasopharingeal</subject><subject>Nasopharynx - virology</subject><subject>Oxidants - therapeutic use</subject><subject>persistent</subject><subject>Physicians</subject><subject>Respiratory diseases</subject><subject>SARS-CoV-2 - drug effects</subject><subject>SARS-CoV-2 - isolation & purification</subject><subject>SARS‐CoV‐2</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Short Communication</subject><subject>Short Communications</subject><subject>Side effects</subject><subject>swab</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Virology</subject><subject>Virus Shedding - drug effects</subject><subject>Viruses</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctKAzEYhYMotl4WvoAMuHIxmmSSzMxGkOIVRbDabcjk0klpJzWZqt35CD6jT2JqtejCTf7A-f6TQw4AewgeIQjx8WjyfIQZKega6CJYsrSEOVoHXYgISxlDtAO2QhhBCIsS403QyXBRoKh2gerXzrcfb--t9pPENrWtbGtdkziT9E_v-1HpuUE8cVLNk3quvBvqJplq716t0nFjcQ82tLppk0YEN62FnzdDLcaJFN7bqO6ADSPGQe9-z23weH720LtMb-4urnqnN6mksKQpyTIpmVYCl6RipCKSkkxmxGhlsFYkN1IqxWhWGKmRoJhWEOaV0bIQBpV5tg1Olr7TWTXRSsZIXoz51NtJzMSdsPyv0tiaD90zz4sSZYRGg4NvA--eZjq0fORmvomZOSYFKuNvMxapwyUlvQvBa7N6AUG-KITHQvhXIZHd_x1pRf40EIHjJfBix3r-vxO_vh0sLT8B3mGbHQ</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Capetti, Amedeo F.</creator><creator>Borgonovo, Fabio</creator><creator>Morena, Valentina</creator><creator>Lupo, Angelica</creator><creator>Cossu, Maria Vittoria</creator><creator>Passerini, Matteo</creator><creator>Dedivitiis, Gianfranco</creator><creator>Rizzardini, Giuliano</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4633-1035</orcidid></search><sort><creationdate>202103</creationdate><title>Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers</title><author>Capetti, Amedeo F. ; Borgonovo, Fabio ; Morena, Valentina ; Lupo, Angelica ; Cossu, Maria Vittoria ; Passerini, Matteo ; Dedivitiis, Gianfranco ; Rizzardini, Giuliano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5095-433cc6eda294b64b4c543c34fedf2ed47fccdd6538fce1a525b007bfec8af1973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Burning</topic><topic>Carrier State - drug therapy</topic><topic>Carrier State - virology</topic><topic>Chemical agents</topic><topic>Coronaviridae</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrogen peroxide</topic><topic>Hydrogen Peroxide - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mucosa</topic><topic>nasopharingeal</topic><topic>Nasopharynx - virology</topic><topic>Oxidants - therapeutic use</topic><topic>persistent</topic><topic>Physicians</topic><topic>Respiratory diseases</topic><topic>SARS-CoV-2 - drug effects</topic><topic>SARS-CoV-2 - isolation & purification</topic><topic>SARS‐CoV‐2</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Short Communication</topic><topic>Short Communications</topic><topic>Side effects</topic><topic>swab</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Virology</topic><topic>Virus Shedding - drug effects</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Capetti, Amedeo F.</creatorcontrib><creatorcontrib>Borgonovo, Fabio</creatorcontrib><creatorcontrib>Morena, Valentina</creatorcontrib><creatorcontrib>Lupo, Angelica</creatorcontrib><creatorcontrib>Cossu, Maria Vittoria</creatorcontrib><creatorcontrib>Passerini, Matteo</creatorcontrib><creatorcontrib>Dedivitiis, Gianfranco</creatorcontrib><creatorcontrib>Rizzardini, Giuliano</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Capetti, Amedeo F.</au><au>Borgonovo, Fabio</au><au>Morena, Valentina</au><au>Lupo, Angelica</au><au>Cossu, Maria Vittoria</au><au>Passerini, Matteo</au><au>Dedivitiis, Gianfranco</au><au>Rizzardini, Giuliano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2021-03</date><risdate>2021</risdate><volume>93</volume><issue>3</issue><spage>1766</spage><epage>1769</epage><pages>1766-1769</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>Asymptomatic and convalescent coronavirus disease 2019 (COVID‐19) subjects may carry severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) for months in their upper respiratory ways. Desiring to permanently clean the mucosal surfaces, we investigated the chemical agents that fit to rapidly degrade the virus. Among these, hydrogen peroxide, initially tested by two of us for tolerability, showed both good performance and acceptable side effects (burning sensation for 15–20 s). We contacted circles of family physicians and the ATS Milano (Territorial Assistance and Prevention Service), and we tested this procedure on eight persistent carriers of SARS‐CoV‐2, performing swabs before the procedure and after it until the reappearance of the virus or until 14 days (the incubation period), keeping the surfaces clean with a hypertonic solution. Our patients had a median time from exposure or symptom onset of 111 days, and three had relapsed after being declared “cured” (two consecutive negative swabs after quarantine). One patient had a baseline negative swab and was excluded, and two successfully ended the 14 days' course, four suppressed viral elimination for 72 h, and one for 48 h, all rebounding to weak positive (cycle thresholds above 24). Although temporarily effective, such measures may have some place in the control of viral shedding to protect the most fragile subjects.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32881014</pmid><doi>10.1002/jmv.26485</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-4633-1035</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0146-6615 |
ispartof | Journal of medical virology, 2021-03, Vol.93 (3), p.1766-1769 |
issn | 0146-6615 1096-9071 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7891345 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Adult Antiviral Agents - therapeutic use Burning Carrier State - drug therapy Carrier State - virology Chemical agents Coronaviridae Coronaviruses COVID-19 COVID-19 - drug therapy Female Humans Hydrogen peroxide Hydrogen Peroxide - therapeutic use Male Middle Aged Mucosa nasopharingeal Nasopharynx - virology Oxidants - therapeutic use persistent Physicians Respiratory diseases SARS-CoV-2 - drug effects SARS-CoV-2 - isolation & purification SARS‐CoV‐2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Short Communication Short Communications Side effects swab Treatment Outcome Viral diseases Virology Virus Shedding - drug effects Viruses |
title | Short‐term inhibition of SARS‐CoV‐2 by hydrogen peroxide in persistent nasopharyngeal carriers |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T12%3A38%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Short%E2%80%90term%20inhibition%20of%20SARS%E2%80%90CoV%E2%80%902%20by%20hydrogen%20peroxide%20in%20persistent%20nasopharyngeal%20carriers&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Capetti,%20Amedeo%20F.&rft.date=2021-03&rft.volume=93&rft.issue=3&rft.spage=1766&rft.epage=1769&rft.pages=1766-1769&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.26485&rft_dat=%3Cproquest_pubme%3E2481910066%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2481910066&rft_id=info:pmid/32881014&rfr_iscdi=true |